N-Acetyl Cysteine (NAC) in the Treatment of Obsessive-Compulsive Disorder: A 16-Week, Double-Blind, Randomised, Placebo-Controlled Study

Randomized Controlled Trial

Jerome Sarris et al. CNS Drugs. 2015 Sep.

Abstract

Background: Obsessive-compulsive disorder (OCD) is a disabling mental illness for which pharmacological and psychosocial interventions are all too often inadequate. Recent preclinical and clinical studies have implicated dysfunction of glutamatergic neurotransmission in the pathophysiology of OCD. The amino acid-based nutraceutical N-acetyl cysteine (NAC) is a safe and readily available agent that has been found to modify the synaptic release of glutamate in subcortical brain regions via modulation of the cysteine-glutamate antiporter.

Objective: The aim of this study was to assess the efficacy and safety of NAC in treating OCD.

Methods: A 16-week, double-blind, placebo-controlled, randomised trial using 3 g/day of NAC (1.5 g twice daily) in 44 participants (aged 18-70 years) with Diagnostic and Statistical Manual of Mental Disorders, 5th edition (DSM-5)-diagnosed OCD, during 2013-2015. The primary outcome measure was the Yale-Brown Obsessive Compulsive Scale (YBOCS), conducted every 4 weeks.

Results: Analysis of the full sample (intention-to-treat) with repeated measures mixed linear modelling revealed a nonsignificant time × treatment interaction for the YBOCS scale total score (p = 0.39). A per-protocol analysis removing protocol violators also failed to show a significant time × treatment interaction for YBOCS total score (p = 0.15). However, a significant time × treatment interaction was observed for the YBOCS 'Compulsions' subscale in favour of NAC (p = 0.013), with a significant reduction observed at week 12 (dissipating at week 16). At 16 weeks, only four (20%) participants were considered 'responders' (YBOCS ≥35% reduction at endpoint) versus four (27%) in the placebo group. The NAC was well-tolerated, aside from more cases of heartburn occurring compared with placebo (p = 0.045).

Conclusion: Further research involving NAC for OCD may require larger samples to detect moderate or small effect sizes, involve dosage or formulation differences, use in concert with exposure therapy, or an additional post-study observational period to mitigate study withdrawal.

Trial registration: ACTRN12613000310763.

PubMed Disclaimer

Cited by

Placebo Effect in Obsessive-Compulsive Disorder (OCD). Placebo Response and Placebo Responders in OCD: The Trend Over Time.
Kotzalidis GD, Del Casale A, Simmaco M, Pancheri L, Brugnoli R, Paolini M, Gualtieri I, Ferracuti S, Savoja V, Cuomo I, De Chiara L, Mosca A, Sani G, Girardi P, Pompili M, Rapinesi C, On Behalf Of The Sapienza Group For The Study Of The Placebo Effect In Psychiatric Disorders. Kotzalidis GD, et al. Curr Neuropharmacol. 2019;17(8):741-774. doi: 10.2174/1570159X16666181026163922. Curr Neuropharmacol. 2019. PMID: 30370851 Free PMC article. Review.
Antiglutamatergic agents for obsessive-compulsive disorder: Where are we now and what are possible future prospects?
Maraone A, Tarsitani L, Pinucci I, Pasquini M. Maraone A, et al. World J Psychiatry. 2021 Sep 19;11(9):568-580. doi: 10.5498/wjp.v11.i9.568. eCollection 2021 Sep 19. World J Psychiatry. 2021. PMID: 34631461 Free PMC article. Review.
Glutamate-Modulating Drugs as a Potential Therapeutic Strategy in Obsessive-Compulsive Disorder.
Marinova Z, Chuang DM, Fineberg N. Marinova Z, et al. Curr Neuropharmacol. 2017;15(7):977-995. doi: 10.2174/1570159X15666170320104237. Curr Neuropharmacol. 2017. PMID: 28322166 Free PMC article. Review.
The Potential of _N_-Acetylcysteine for Treatment of Trichotillomania, Excoriation Disorder, Onychophagia, and Onychotillomania: An Updated Literature Review.
Lee DK, Lipner SR. Lee DK, et al. Int J Environ Res Public Health. 2022 May 24;19(11):6370. doi: 10.3390/ijerph19116370. Int J Environ Res Public Health. 2022. PMID: 35681955 Free PMC article. Review.
Individualized Immunological Data for Precise Classification of OCD Patients.
Lamothe H, Baleyte JM, Smith P, Pelissolo A, Mallet L. Lamothe H, et al. Brain Sci. 2018 Aug 9;8(8):149. doi: 10.3390/brainsci8080149. Brain Sci. 2018. PMID: 30096863 Free PMC article. Review.

References

1. Biol Psychiatry. 2009 Jan 1;65(1):75-83 - PubMed
1. Neuropsychobiology. 2010;61(4):210-4 - PubMed
1. Neurosci Biobehav Rev. 2015 Aug;55:294-321 - PubMed
1. Biol Psychiatry. 2013 Feb 15;73(4):321-8 - PubMed
1. Prog Neuropsychopharmacol Biol Psychiatry. 2009 Mar 17;33(2):363-6 - PubMed

N-Acetyl Cysteine (NAC) in the Treatment of Obsessive-Compulsive Disorder: A 16-Week, Double-Blind, Randomised, Placebo-Controlled Study - PubMed (original) (raw)